Fennec Pharmaceuticals (FENC) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Valneva (VALN) over the past year, gaining 66.1% versus a loss of 40.1%. Over five years, FENC leads with a +35.8% price change compared with -91.3% for VALN. Valneva is the larger company by market cap ($490.9 million vs $462.1 million), about 1.1 times the size.
On valuation, Valneva trades at a lower forward P/E (4.3x vs 12.5x for Fennec Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | VALN |
|---|---|---|
| Share price | $13.09 | $5.16 |
| Market cap | $462.14M | $490.86M |
| 1-day change | -2.68% | -3.82% |
| YTD return | +70.00% | -41.50% |
| 1-year return | +66.12% | -40.14% |
| 5-year return | +35.79% | -91.34% |
| P/E ratio (TTM) | 436.33 | — |
| Forward P/E | 12.47 | 4.34 |
| EPS (TTM) | $0.03 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.64M | — |
| Revenue growth (YoY) | -6.09% | — |
| Net income (latest FY) | $-9.74M | — |
| Operating margin | -14.07% | — |
| Net margin | -21.82% | — |
| 52-week high | $13.85 | $12.18 |
| 52-week low | $5.65 | $4.75 |
| Distance from 52-week high | -5.49% | -57.64% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +34.45% | +137.98% |
| Average volume | 220.87K | 23.10K |
| Shares outstanding | 35.31M | 95.13M |
| Employees | 35 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed VALN by 106.3 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
FENC vs VALN FAQ
Which is bigger, Fennec Pharmaceuticals or Valneva?
Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $462.14M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, FENC or VALN?
FENC returned +66.12% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.